Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABUS

Arbutus Biopharma Corp

4.71

Aug 17 • 3:59 PM ET +0.04 (0.86%)

4.71

Aftermarket • 7:34 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR RYTM INCY BMRN CRNX VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA IWC KOMP

Scroll to Statements

Index	RUT
Market Cap	931.86M
Enterprise Value	842.86M
Income	153.05M
Sales	181.72M
Book/sh	1.31
Cash/sh	0.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	19
IPO	Jul 23, 2007

P/E	6.01
Forward P/E	-
PEG	-
P/S	5.13
P/B	3.60
P/C	10.06
P/FCF	-
EV/EBITDA	5.72
EV/Sales	4.64
Quick Ratio	81.42
Current Ratio	81.42
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	0.78
EPS next Y	-0.08
EPS next Q	-0.02
EPS this Y	535.29%
EPS next Y	-110.81%
EPS next 5Y	-
EPS past 3/5Y	27.58% 29.45%
Sales past 3/5Y	-28.80% 15.29%
EPS Y/Y TTM	376.44%
Sales Y/Y TTM	1078.78%
EPS Q/Q	-298.47%
Sales Q/Q	-90.56%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-50.00% 44.86%

Insider Own	20.46%
Insider Trans	0.00%
Inst Own	71.26%
Inst Trans	2.35%
ROA	81.13%
ROE	89.58%
ROIC	58.45%
Gross Margin	99.98%
Oper. Margin	81.13%
Profit Margin	84.23%
SMA20	4.74%
SMA50	3.56%
SMA200	5.67%
Trades

Shs Outstand	197.63M
Shs Float	157.37M
Short Float	12.86%
Short Ratio	10.21
Short Interest	20.24M
52W High	5.38 -12.45%
52W Low	3.31 42.30%
Volatility	3.37% 3.80%
ATR (14)	0.18
RSI (14)	56.72
Beta	0.61
Rel Volume	0.70
Avg Volume	1.98M
Volume	1,388,208

Perf Week	2.61%
Perf Month	3.29%
Perf Quarter	11.08%
Perf Half Y	18.34%
Perf YTD	-2.08%
Perf Year	39.97%
Perf 3Y	127.54%
Perf 5Y	41.87%
Perf 10Y	30.47%
Recom	1.00
Target Price	5.50
Prev Close	4.67
Price	4.71
Change %	0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

Aug-12-26 07:37AM	Arbutus: Q2 Earnings Snapshot (Associated Press)
07:30AM	Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-17-26 06:07AM	Arbutus, Sanofi escalate mRNA patent fights; InnoCares TYK2 contender advances (BioPharma Dive)
Jul-16-26 02:41PM	ABUS Stock On Track For Best Day In About Two Months Whats The Moderna Connection? (Stocktwits)
07:30AM	Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders (GlobeNewswire)
02:28PM	Loading…
Jul-07-26 02:28PM	ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week (Stocktwits)
May-13-26 07:36AM	Arbutus: Q1 Earnings Snapshot (Associated Press)
07:30AM	Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-26 09:05AM	Moderna Q1 2026 earnings beat on international COVID vaccine sales (Quartz)
08:27AM	Moderna sees revenue bump from international COVID vaccine sales (BioPharma Dive)
Apr-15-26 07:30AM	Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B (GlobeNewswire)
Mar-23-26 07:39AM	Arbutus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-26 04:50PM	These Stocks Are Todays Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More (Barrons.com)
04:32PM	Moderna Stock Shoots Up on $2.3 Billion Patent Settlement (The Wall Street Journal)
04:02PM	Loading…
04:02PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
10:18AM	Moderna to pay up to $2.25B to settle COVID vaccine patent matter (Proactive)
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:52AM	Moderna shares jump as settlement removes major legal overhang (Investing.com)
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
08:14AM	Moderna Just Settled a Lawsuit. What It Means for the Stock. (Barrons.com)
05:25AM	Moderna Stock Rallies. This Big Risk Just Got Eliminated. (Barrons.com)
Mar-03-26 06:58PM	Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant (The Wall Street Journal)
04:15PM	Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
Feb-18-26 05:18PM	Moderna Loses 2 Defenses In Patent Fight (GuruFocus.com)
Feb-06-26 12:33PM	Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling (TheStreet)
12:00PM	Loading…
Jan-12-26 12:00PM	Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 07:30AM	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Oct-07-25 08:00AM	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025 (GlobeNewswire)
Oct-03-25 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Sep-17-25 09:40AM	Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-01-25 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:45AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-25-25 07:30AM	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus (GlobeNewswire)
May-14-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:39AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-07-25 02:01AM	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 (GlobeNewswire)
Apr-25-25 09:40AM	Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-24-25 10:02AM	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-23-25 02:01AM	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 12:00PM	All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy (Zacks)
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 09:48AM	Arbutus Biopharma: A Wing And A Prayer (Seeking Alpha) +7.03%
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
07:01AM	Novo gains Lexicon obesity drug; CRISPR COO to step down (BioPharma Dive)
Mar-27-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-25 03:45PM	As Vaccine Skepticism Mounts, Modernas Business Grows More Precarious (Barrons.com)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire)
Feb-25-25 07:00AM	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO (GlobeNewswire)
Feb-12-25 09:24AM	Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-16-25 11:22AM	Jim Cramer on Arbutus Biopharma Corporation (ABUS): It Loses Money (Insider Monkey)
Jan-13-25 07:30AM	Arbutus Provides 2025 Corporate and Financial Update (GlobeNewswire)
Dec-06-24 08:20AM	Heres Why Arbutus (ABUS) Surged in Q3 (Insider Monkey)
Dec-03-24 08:00AM	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors (Business Wire)
Nov-26-24 07:30AM	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat (GlobeNewswire)
Nov-15-24 11:02AM	Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon (GlobeNewswire)
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
Nov-14-24 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 02:12AM	Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
02:07AM	Q3 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:45AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-24 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

M.B.A.Ms. Lindsay Androski J.D.

Chief Financial OfficerMr. Tuan Nguyen

General CounselMr. Andrew J. Sung

J.D.Mr. R. Hector Mackay-Dunn B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABUS

Arbutus Biopharma Corp

Upgrade your Finviz experience